Reply to Farolfi et al and Haines et al.

Tewari, Krishnansu S; Monk, Bradley J; Burger, Robert A

Tewari, Krishnansu S; Monk, Bradley J; Burger, Robert A.

Afiliação

Tewari KS; Krishnansu S. Tewari, MD, University of California Irvine, Orange, CA; Bradley J. Monk, MD, Creighton University School of Medicine, Omaha, NE; and Robert A. Burger, MD, University of Pennsylvania Perelman School of Medicine,Philadelphia, PA.
Monk BJ; Krishnansu S. Tewari, MD, University of California Irvine, Orange, CA; Bradley J. Monk, MD, Creighton University School of Medicine, Omaha, NE; and Robert A. Burger, MD, University of Pennsylvania Perelman School of Medicine,Philadelphia, PA.
Burger RA; Krishnansu S. Tewari, MD, University of California Irvine, Orange, CA; Bradley J. Monk, MD, Creighton University School of Medicine, Omaha, NE; and Robert A. Burger, MD, University of Pennsylvania Perelman School of Medicine,Philadelphia, PA.

J Clin Oncol ; 38(2): 173-174, 2020 01 10.

Article em En | MEDLINE | ID: mdl-31697589

Assuntos

Carcinoma Epitelial do Ovário; Neoplasias Ovarianas; Bevacizumab; Feminino; Humanos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Carcinoma Epitelial do Ovário Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google